Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — H1 2020 Earnings Presentation
22 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's earnings presentation, August 2020
Slide 1: Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. August 2020 300347.SZ / 3347.HK
Slide 2: Disclaimer
Disclaimer This document is purely as a summary and is not intended to provide any representation, in whole or in part, of the relevant matters. For further information, please refer to the 2020 interim report and relevant announcements published on the websites of the Shenzhen Stock Exchange (www.s
Slide 3: Table of Contents
2020 Interim Results Table of Contents 1. 2020 Interim Results 1 2. Business Update 4 3. Financial Overview 9 4. Corporate Update 12
Slide 4: 2020 Interim Results
2020 Interim Results
Slide 5: 2020 Interim Snapshot
2020 Interim Snapshot revenue growth despite 5 1 #1 9.3% COVID-19 impacts in China(1) clinical CRO in China (1) Financial Leadership Highlights GP margin; slightly involvement in Class I new 48.1% improved vs 1H2019 >50% drug approvals in China (2) Operation sites Trials and ongoing drug clinical 5,
Slide 6: Key Financials for 1H2020
Key Financials for 1H2020 Revenue Gross Profit and Margin Net Profit and Margin (RMB mm) (RMB mm) 46.5% 48.1% (RMB mm) 43.2% 72.2% 1,452.0 1,328.2 1,049.0 741.0 5.7% 700.9 Change in fair value 698.1 632.7 of financial 618.0 assets at 573.3 FVTPL(1) 156.2 711.0 13.3% 627.3 417.1 416.3 1H2019 1H2020 1
Slide 7: 1Q and 2Q2020 Business Segment Performance
1Q and 2Q2020 Business Segment Performance Clinical Trial Solutions Clinical-related and Laboratory Services (RMB mm) (RMB mm) 408.4 388.6 373.2 350.0 352.4 327.7 302.6 277.3 1Q2019 1Q2020 2Q2019 2Q2020 1Q2019 1Q2020 2Q2019 2Q2020 3
Slide 8: Business Update
Business Update
Slide 9: Clinical Trial Solutions
Clinical Trial Solutions Revenue (RMB mm) Segment revenue increased 13.3% YoY to RMB711.0mm in 1H2020 Acquisition of Beijing Yaxincheng Medical 1,346.7 InfoTech Co., Ltd. (“Yaxincheng”) in July 2019 1,107.6 and Shanghai Mosim Medical Technology Co., 750.4 711.0 Ltd. (“Mosim”) in January 2020 con
Slide 10: Clinical Trial Solutions (Cont’d)
Clinical Trial Solutions (Cont’d) Project Status Update for Key Business Units Number of Ongoing Drug Clinical Research Projects by Phase (1) Number of Ongoing Drug Clinical Research Projects by Region (1) 349 349 21 17 283 287 24 283 287 8 10 12 85 19 10 24 218 107 218 83 70 6 88 92 6 24 76 74 78 5
Slide 11: Clinical-related and Lab Services
Clinical-related and Lab Services Revenue (RMB mm) Segment revenue increased 5.7% YoY to RMB741.0m in 1H2020 1,456.6 1,191.9 932.1 Segment revenue growth slowed down 700.9 741.0 primarily due to the impact of COVID-19 outbreak on our services offered in this segment 2017 2018 2019 1H2019 1H2020
Slide 12: Clinical-related and Lab Services (Cont’d)
Clinical-related and Lab Services (Cont’d) Project Status Update for Key Business Units Data Management and Statistical Analysis Site Management Laboratory Services Conducted 177 by team based Projects completed overseas Completed 1,941 Completed 979 393 Conducted by team based in 1,581 1,512 China
Slide 13: Other Operating Updates
Other Operating Updates Total employees increased 7.1% to 5,312 as of June 30, 2020 from 4,959 as of December 31, 2019 Employees Mix by Function as of June 30, 2020 Employees Mix by Geography as of June 30, 2020 Management and administration Overseas, Hong Kong, Macau and Taiwan Marketing and 338 bu
Slide 14: Financial Overview
Financial Overview QD Toermed
Slide 15: Revenue Breakdown by PRC and Overseas Markets
Revenue Breakdown by PRC and Overseas Markets Revenue – China Revenue – Overseas (RMB mm) (RMB mm) YoY Growth: (0.6%) 845.8 609.9 606.2 718.3 1H2019 1H20200 1H2019 1H2020 Revenue Breakdown by Region Overseas revenue decreased by 0.6% year-over-year primarily due to the impact 42% of the COVID-19 o
Slide 16: Operating Expenses
Operating Expenses Selling and Marketing Expenses and as % of Revenue Administrative Expenses and as % of Revenue (RMB mm) 2.8% 2.7% (RMB mm) 11.3% 12.8% 186.1 149.8 37.1 39.8 1H2019 1H2020 1H2019 1H2020 R&D Expenses and as % of Revenue Share-based Compensation and as % of Revenue (RMB mm) 4.4% 5.0%
Slide 17: Summary of Investment Activities
Summary of Investment Activities Realized Investment Gain and Fair Value Gain(1) (RMB mm) Portfolio includes 57 companies in the healthcare industry and 39 investment funds as of June 30, 632.7 2020 RMB 3,240mm balance as of June 30, 2020 1H19’-1H20’ YoY Growth Invested RMB101.2mm in unlisted equiti
Slide 18: Corporate Update
Corporate Update QD Tvermed
Slide 19: Environmental, Social, and Corporate Governance
Environmental, Social, and Corporate Governance We have published our 2019 Sustainability Report in both Chinese and English 12
Slide 20: Fighting COVID-19
Fighting COVID-19 Tigermed team is at the forefront of the fight against the pandemic During this unprecedented pandemic, Tigermed has adopted strict requirements firmwide to ensure the safety of our employees. Tigermed has also made fund and PPE donations to the society. Tigermed Team is honored to
Slide 21: Tigermed team fighting COVID-19
Tigermed team fighting COVID-19
Slide 22: 300347.SZ 3347.HK
300347.SZ 3347.HK Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com
Hangzhou Tigermed Consulting — H1 2020 Earnings Presentation on 6ix